prostate cancer; psa; screening

19:38-32:10 Summary This virtual talk on men's health focused on the disparities in healthcare utilization between men and women, as well as the importance of early intervention and lifestyle choices. It also highlighted the prevalence of Peyronie's disease and the available treatments...

Convincing your PCP partners to screen for the early warning signs of prostate cancer does not have to be complicated. Learn how to develop an easy-to-follow risk stratification pathway to share with your PCP partners in this 12-minute talk from E. David Crawford, MD, Editor-in-Chief of Grand...

Mark Scholz, MD, is a medical oncologist who specializes exclusively in prostate cancer. Here, he gives a detailed survey of the best tools for staging newly diagnosed prostate cancer, describes the implications of the new PSMA PET scan, and answers other questions related to the diagnostic and...

Prostate-specific antigen (PSA) is one of the best-known biomarkers for screening, diagnosis, and follow-up of patients for prostate cancer. Owing to several inherent limitations with PSA, various newer blood and urinary-based biomarkers have been evaluated in pursuit of better detection and...